In recent years, endocrine therapy (ET), an effective systemic treatment for the management of estrogen receptor (ER)-positive breast cancers, has regained interest as a neoadjuvant therapy based on evidence that ET can fulfill the aim of neoadjuvant systemic treatment for tumor shrinkage as well as elucidate important clinical information on endocrine sensitivity that enables the prognostication of patients. Moreover, neoadjuvant endocrine therapy (NET) potentially provides an opportunity for early assessment of the clinical efficacy of novel agents. Furthermore, recently reported trials have generated evidence for a more tailored approach for perioperative management of ER-positive breast cancer using clinical and molecular biomarkers, and this has provided a rationale that enables the broadening of clinical indications for NET. This review discusses the current evidence for NET, the evolution of NET trials, clinical indications, and NET-based treatment strategies.

中文翻译：

---

ER 阳性乳腺癌的新辅助内分泌治疗：演变、适应症和定制治疗策略。

近年来，内分泌治疗（ET）作为一种治疗雌激素受体（ER）阳性乳腺癌的有效全身治疗方法，由于有证据表明内分泌治疗可以实现肿瘤新辅助全身治疗的目的，因此作为一种新辅助治疗重新引起了人们的兴趣。缩小并阐明有关内分泌敏感性的重要临床信息，从而能够预测患者的预后。此外，新辅助内分泌治疗（NET）可能为早期评估新药的临床疗效提供机会。此外，最近报道的试验已经为使用临床和分子生物标志物对 ER 阳性乳腺癌围手术期管理采取更量身定制的方法提供了证据，这为扩大 NET 的临床适应症提供了理论基础。本综述讨论了 NET 的当前证据、NET 试验的演变、临床适应症和基于 NET 的治疗策略。